reboxetine has been researched along with sch 23390 in 1 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (sch 23390) | Trials (sch 23390) | Recent Studies (post-2010) (sch 23390) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 803 | 0 | 585 |
| Protein | Taxonomy | reboxetine (IC50) | sch 23390 (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Homo sapiens (human) | 1.0405 | |
| D | Rattus norvegicus (Norway rat) | 0.001 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.0461 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.0011 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0006 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.3891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Björkholm, C; Jardemark, K; Malmerfelt, A; Marcus, MM; Nyberg, S; Schilström, B; Svensson, TH | 1 |
1 other study(ies) available for reboxetine and sch 23390
| Article | Year |
|---|---|
Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Antipsychotic Agents; Avoidance Learning; Benzazepines; Dibenzothiazepines; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Male; Membrane Potentials; Morpholines; N-Methylaspartate; Norepinephrine Plasma Membrane Transport Proteins; Nucleus Accumbens; Prefrontal Cortex; Pyramidal Cells; Quetiapine Fumarate; Raclopride; Rats; Reboxetine | 2013 |